iShares Self-Driving EV and Tech ETF (ARCA: IDRV)

Ultime notizie per iShares Self-Driving EV and Tech ETF (ARCA:IDRV)

Consumer Cyclical

Industrials

Basic Materials

Other

Technology

Financial Services

The index is composed of equity securities of companies listed in one of 43 developed or emerging market countries that derive a certain specified percentage of their revenue from selected autonomous or electric vehicle-related industries, as defined by IDI. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index. It is non-diversified.

Rivian Automotive

Tesla, Inc.

Lucid Group Inc

Denso Corp

Byd Co Ltd H

Xpeng Inc-A Shrs

Abb Ltd

Schneider Electric Se

Lg Energy Solution

iShares Self-Driving EV and Tech ETF

Earnings

News

Comerica Q3 2024 Adj. EPS $1.37 Beats $1.16 Estimate, Sales $811.000M Miss $811.617M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Delays impact 40% of Biden administration's biggest climate projects - FT

Trump would consider ending EV tax credit, naming Elon Musk as adviser - report

The Fed Finally Joins The 'Rate Cut' Party

Portfolio Implications Of Powell's 'Whatever It Takes' Moment

Investing In The Next Generation Of Environmental Tech Breakthroughs

How The U.S. Election Could Impact The Energy Transition

Resilient U.S. Retail Sales Suggests Fed Decision Will Be A Coin Toss

DoE awards $3B for 25 projects to boost U.S. battery production

Winding Road Ahead For China's EV Growth

IDRV: Starting To Turn The Car Around, Buy Rating

AAAU

ABAT

ACES

ACTV

AFMC

AFSM

AIRR

ARKK

ARKQ

AVUV

BAPR

BATT

BBRE

BBSC

BGLD

BKSE

BRZU

BYDDF

BYDDY

CALF

CARZ

CBSE

CNRG

CRBN

CTEC

CTEX

DEEP

DFAS

DGRS

DNFGF

DNFGY

DRIV

DUSL

DWAS

EBIZ

EFRA

ENLAY

EQNR

ERTH

ESML

ETEC

EVAV

EWZS

FDIS

FDRV

FIBR

FIDU

FLBR

FLQS

FNDA

FPRO

FREL

FRNW

FSTA

FTXR

GBIL

GCLN

GELYF

GELYY

GLDI

GLDM

GLRY

GLTR

GOVT

GOVZ

GRID

GRNTF

GSSC

GWLLF

GWLLY

HAIL

HOMZ

HSMV

HYDR

IAUM

IBUY

ICLN

IDRV

IEDI

IGLD

INDS

ISCB

ISCG

ISCV

ISHP

ISMD

IVOO

IVOV

IVRA

JHSC

JJETF

JPSE

JSML

KAPR

KARS

KBWY

KCCA

KEUA

KJAN

KJUL

KRBN

LGOV

MAGS

MGMT

MORT

NAIL

NBCT

NETL

NURE

NUSC

OILK

OLOXF

OMFS

ONLN

OSCV

OUNZ

Comments

iShares Self-Driving EV and Tech ETF

Notizie

Ultime notizie per iShares Self-Driving EV and Tech ETF (ARCA:IDRV)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO